Skip to main content
Top
Published in: Endocrine 3/2015

01-12-2015 | Original Article

Predictive value of intratumoral heterogeneity of F-18 FDG uptake for characterization of thyroid nodules according to Bethesda categories of fine needle aspiration biopsy results

Authors: Seong-Jang Kim, Samuel Chang

Published in: Endocrine | Issue 3/2015

Login to get access

Abstract

The current study was aimed to investigate the clinical value of intratumoral heterogeneity of F-18 FDG uptake for characterization of thyroid nodule (TN) with inconclusive fine-needle aspiration biopsy (FNAB) results. The current study enrolled 200 patients who showed F-18 FDG incidentaloma and were performed FNAB. The intratumoral heterogeneity of F-18 FDG uptake was represented as the heterogeneity factor (HF), defined as the derivative (dV/dT) of a volume-threshold function for a primary tumor. The diagnostic and predictive values of HF and F-18 FDG PET/CT parameters were evaluated for characterization of inconclusive FNAB results. Among F-18 FDG PET/CT parameters, SUVmax, MTV, and TLG of malignant group were statistically higher than those of Bethesda category of suspicious malignant group. However, HF values were not statistically different between the groups of Bethesda categories (Kruskal–Wallis statistics, 9.924; p = 0.0774). In ROC analysis, when HF > 2.751 was used as cut-off value, the sensitivity and specificity for prediction of malignant TN were 100 % (95 % CI 69.2–100 %) and 60 % (95 % CI 42.1–76.1 %), respectively. The AUC was 0.826 (95 % CI 0.684–0.922) and standard error was 0.0648 (p < 0.0001). In conclusion, the intratumoral heterogeneity of F-18 FDG uptake represented by HF could be a predictor for characterization of TN with inconclusive FNAB results. Additional large population-based prospective studies are needed to validate the diagnostic utility of HF of F-18 FDG PET/CT.
Literature
1.
go back to reference C. Hambleton, E. Kandil, Appropriate and accurate diagnosis of thyroid nodule: a review of thyroid fine-needle aspiration. Int. J. Clin. Exp. Med. 6, 413–422 (2013)PubMedCentralPubMed C. Hambleton, E. Kandil, Appropriate and accurate diagnosis of thyroid nodule: a review of thyroid fine-needle aspiration. Int. J. Clin. Exp. Med. 6, 413–422 (2013)PubMedCentralPubMed
2.
go back to reference M. Goldfarb, S. Gondek, C. Soloranzo, J.I. Lew, Surgeon-performed ultrasound can predict benignity in thyroid nodules. Surgery 50, 436–441 (2011)CrossRef M. Goldfarb, S. Gondek, C. Soloranzo, J.I. Lew, Surgeon-performed ultrasound can predict benignity in thyroid nodules. Surgery 50, 436–441 (2011)CrossRef
3.
go back to reference D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)CrossRefPubMed D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel, E.L. Mazzaferri, B. McIver, F. Pacini, M. Schlumberger, S.I. Sherman, D.L. Steward, R.M. Tuttle, Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)CrossRefPubMed
4.
5.
go back to reference J.R. Porterfield Jr, C.S. Grant, D.S. Dean, G.B. Thompson, D.R. Farley, M.L. Richards, C.C. Reading, J.W. Charboneau, B.K. Vollrath, T.J. Sebo, Reliability of benign fine needle aspiration cytology of large thyroid nodules. Surgery 144, 963–968 (2008)CrossRefPubMed J.R. Porterfield Jr, C.S. Grant, D.S. Dean, G.B. Thompson, D.R. Farley, M.L. Richards, C.C. Reading, J.W. Charboneau, B.K. Vollrath, T.J. Sebo, Reliability of benign fine needle aspiration cytology of large thyroid nodules. Surgery 144, 963–968 (2008)CrossRefPubMed
6.
go back to reference J.B. Ogilvie, E.J. Piatigorsky, O.H. Clark, Current status of fine needle aspiration for thyroid nodules. Adv. Surg. 40, 223–238 (2006)CrossRefPubMed J.B. Ogilvie, E.J. Piatigorsky, O.H. Clark, Current status of fine needle aspiration for thyroid nodules. Adv. Surg. 40, 223–238 (2006)CrossRefPubMed
7.
go back to reference E.S. Cibas, S.Z. Ali, NCI Thyroid FNA State of the Science Conference, The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 132, 658–665 (2009)CrossRefPubMed E.S. Cibas, S.Z. Ali, NCI Thyroid FNA State of the Science Conference, The Bethesda system for reporting thyroid cytopathology. Am. J. Clin. Pathol. 132, 658–665 (2009)CrossRefPubMed
8.
go back to reference S. Rorive, N. D’Haene, C. Fossion, I. Delpierre, N. Abarguia, F. Avni, C. Decaestecker, I. Salmon, Ultrasound-guided fine-needle aspiration of thyroid nodules: stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur. J. Endocrinol. 162, 1107–1115 (2010)CrossRefPubMed S. Rorive, N. D’Haene, C. Fossion, I. Delpierre, N. Abarguia, F. Avni, C. Decaestecker, I. Salmon, Ultrasound-guided fine-needle aspiration of thyroid nodules: stratification of malignancy risk using follicular proliferation grading, clinical and ultrasonographic features. Eur. J. Endocrinol. 162, 1107–1115 (2010)CrossRefPubMed
9.
go back to reference L.J. Layfield, E.S. Cibas, H. Gharib, S.J. Mandel, Thyroid aspiration cytology: current status. CA Cancer J. Clin. 59, 99–110 (2009)CrossRefPubMed L.J. Layfield, E.S. Cibas, H. Gharib, S.J. Mandel, Thyroid aspiration cytology: current status. CA Cancer J. Clin. 59, 99–110 (2009)CrossRefPubMed
10.
go back to reference G.H. Heppner, Tumor heterogeneity. Cancer Res. 44, 2259–2265 (1984)PubMed G.H. Heppner, Tumor heterogeneity. Cancer Res. 44, 2259–2265 (1984)PubMed
11.
12.
go back to reference M.E. Lleonart, P. Martin-Duque, R. Sanchez-Prieto, A. Moreno, S. Cajal, Tumor heterogeneity: morphological, molecular and clinical implications. Histol. Histopathol. 15, 881–889 (2000)PubMed M.E. Lleonart, P. Martin-Duque, R. Sanchez-Prieto, A. Moreno, S. Cajal, Tumor heterogeneity: morphological, molecular and clinical implications. Histol. Histopathol. 15, 881–889 (2000)PubMed
13.
go back to reference B. Huang, T. Chan, D.L. Kwong, W.K. Chan, P.L. Khong, Nasopharyngeal carcinoma: investigation of intratumoral heterogeneity with FDG PET/CT. AJR Am. J. Roentgenol. 199, 169–174 (2012)CrossRefPubMed B. Huang, T. Chan, D.L. Kwong, W.K. Chan, P.L. Khong, Nasopharyngeal carcinoma: investigation of intratumoral heterogeneity with FDG PET/CT. AJR Am. J. Roentgenol. 199, 169–174 (2012)CrossRefPubMed
14.
go back to reference F. Tixier, C.C. Le Rest, M. Hatt, N. Albarghach, O. Pradier, Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predict response to concomitant radiochemotherapy in esophageal cancer. J. Nucl. Med. 52, 369–378 (2011)PubMedCentralCrossRefPubMed F. Tixier, C.C. Le Rest, M. Hatt, N. Albarghach, O. Pradier, Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predict response to concomitant radiochemotherapy in esophageal cancer. J. Nucl. Med. 52, 369–378 (2011)PubMedCentralCrossRefPubMed
15.
go back to reference G.J. Cook, C. Yip, M. Siddique, V. Goh, S. Chicklore, A. Roy, P. Marsden, S. Ahmad, D. Landau, Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J. Nucl. Med. 54, 19–26 (2013)CrossRefPubMed G.J. Cook, C. Yip, M. Siddique, V. Goh, S. Chicklore, A. Roy, P. Marsden, S. Ahmad, D. Landau, Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J. Nucl. Med. 54, 19–26 (2013)CrossRefPubMed
16.
go back to reference S.H. Son, D.H. Kim, C.M. Hong, C.Y. Kim, S.Y. Jeong, S.W. Lee, J. Lee, B.C. Ahn, Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer 14, 585–595 (2014)PubMedCentralCrossRefPubMed S.H. Son, D.H. Kim, C.M. Hong, C.Y. Kim, S.Y. Jeong, S.W. Lee, J. Lee, B.C. Ahn, Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast. BMC Cancer 14, 585–595 (2014)PubMedCentralCrossRefPubMed
17.
go back to reference E.A. Kidd, P.W. Grigsby, Intratumoral metabolic heterogeneity of cervical cancer. Clin. Cancer Res. 14, 5236–5241 (2008)CrossRefPubMed E.A. Kidd, P.W. Grigsby, Intratumoral metabolic heterogeneity of cervical cancer. Clin. Cancer Res. 14, 5236–5241 (2008)CrossRefPubMed
18.
go back to reference T.R. Miller, P.W. Grigsby, Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 53, 353–359 (2002)CrossRefPubMed T.R. Miller, P.W. Grigsby, Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 53, 353–359 (2002)CrossRefPubMed
19.
go back to reference M. Soret, S.L. Bachrach, I. Buvat, Partial volume effect in PET tumor imaging. J. Nucl. Med. 48, 932–945 (2007)CrossRefPubMed M. Soret, S.L. Bachrach, I. Buvat, Partial volume effect in PET tumor imaging. J. Nucl. Med. 48, 932–945 (2007)CrossRefPubMed
20.
21.
go back to reference J.A. Sipos, E.L. Mazzaferri, Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. (R. Coll. Radiol.) 22, 395–404 (2010)CrossRef J.A. Sipos, E.L. Mazzaferri, Thyroid cancer epidemiology and prognostic variables. Clin. Oncol. (R. Coll. Radiol.) 22, 395–404 (2010)CrossRef
22.
go back to reference B. Miller, S. Burkey, G. Lindberg, W.H. Snyder 3rd, F.E. Nwariaku, Prevalence of malignancy within cytologically indeterminate thyroid nodules. Am. J. Surg. 188, 459–462 (2004)CrossRefPubMed B. Miller, S. Burkey, G. Lindberg, W.H. Snyder 3rd, F.E. Nwariaku, Prevalence of malignancy within cytologically indeterminate thyroid nodules. Am. J. Surg. 188, 459–462 (2004)CrossRefPubMed
23.
go back to reference G.M. Scabas, G.A. Staerkel, S.E. Shapiro, Fine-needle aspiration of the thyroid and correlation with hispathology in a contemporary series of 240 patients. Am. J. Surg. 186, 702–710 (2003)CrossRef G.M. Scabas, G.A. Staerkel, S.E. Shapiro, Fine-needle aspiration of the thyroid and correlation with hispathology in a contemporary series of 240 patients. Am. J. Surg. 186, 702–710 (2003)CrossRef
24.
go back to reference S.M. Khoncarly, S.W. Tamarkin, C.R. McHenry, Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy ? Surgery 156, 967–971 (2014)CrossRefPubMed S.M. Khoncarly, S.W. Tamarkin, C.R. McHenry, Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy ? Surgery 156, 967–971 (2014)CrossRefPubMed
25.
go back to reference N. Batawil, T. Alkordy, Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules. EJSO 40, 182–186 (2014)CrossRefPubMed N. Batawil, T. Alkordy, Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules. EJSO 40, 182–186 (2014)CrossRefPubMed
26.
go back to reference H. Li, K.A. Robinson, B. Anton, I.J. Saldanha, P.W. Ladenson, Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 96, E1719–E1726 (2011)CrossRefPubMed H. Li, K.A. Robinson, B. Anton, I.J. Saldanha, P.W. Ladenson, Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J. Clin. Endocrinol. Metab. 96, E1719–E1726 (2011)CrossRefPubMed
27.
go back to reference Y.E. Nikiforov, N.P. Ohori, S.P. Hodak, S.E. Carty, S.O. LeBeau, R.L. Ferris, L. Yip, R.R. Seethala, M.E. Tublin, M.T. Stang, C. Coyne, J.T. Johnson, A.F. Stewart, M.N. Nikiforova, Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 96, 3390–3397 (2011)PubMedCentralCrossRefPubMed Y.E. Nikiforov, N.P. Ohori, S.P. Hodak, S.E. Carty, S.O. LeBeau, R.L. Ferris, L. Yip, R.R. Seethala, M.E. Tublin, M.T. Stang, C. Coyne, J.T. Johnson, A.F. Stewart, M.N. Nikiforova, Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Metab. 96, 3390–3397 (2011)PubMedCentralCrossRefPubMed
28.
go back to reference D. Vriens, E.M. Adang, R.T. Netea-Maier, J.W. Smit, J.H. de Wilt, W.J. Oyen, L.F. de Geus-Oei, Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J. Clin. Endocrinol. Metab. 99, 3263–3274 (2014)CrossRefPubMed D. Vriens, E.M. Adang, R.T. Netea-Maier, J.W. Smit, J.H. de Wilt, W.J. Oyen, L.F. de Geus-Oei, Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. J. Clin. Endocrinol. Metab. 99, 3263–3274 (2014)CrossRefPubMed
29.
go back to reference A.L. Traugott, F. Dehdashti, K. Trinkaus, M. Cohen, E. Fialkowski, F. Quayle, H. Hussain, R. Davila, L. Ylagan, J.F. Moley, Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18 F-fluorodeoxyglucose positron emission tomography: interim analysis. World J. Surg. 34, 1247–1253 (2010)PubMedCentralCrossRefPubMed A.L. Traugott, F. Dehdashti, K. Trinkaus, M. Cohen, E. Fialkowski, F. Quayle, H. Hussain, R. Davila, L. Ylagan, J.F. Moley, Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18 F-fluorodeoxyglucose positron emission tomography: interim analysis. World J. Surg. 34, 1247–1253 (2010)PubMedCentralCrossRefPubMed
30.
go back to reference D. Deandreis, A. Al Ghuzlan, A. Auperin, P. Vielh, B. Caillou, L. Chami, J. Lumbroso, J.P. Travagli, D. Hartl, E. Baudin, M. Schlumberger, S. Leboulleux, Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 22, 165–172 (2012)CrossRefPubMed D. Deandreis, A. Al Ghuzlan, A. Auperin, P. Vielh, B. Caillou, L. Chami, J. Lumbroso, J.P. Travagli, D. Hartl, E. Baudin, M. Schlumberger, S. Leboulleux, Is (18)F-fluorodeoxyglucose-PET/CT useful for the presurgical characterization of thyroid nodules with indeterminate fine needle aspiration cytology? Thyroid 22, 165–172 (2012)CrossRefPubMed
31.
go back to reference J.M. Kim, J.S. Ryu, T.Y. Kim, W.B. Kim, G.Y. Kwon, G. Gong, D.H. Moon, S.C. Kim, S.J. Hong, Y.K. Shong, 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J. Clin. Endocrinol. Metab. 92, 1630–1634 (2007)CrossRefPubMed J.M. Kim, J.S. Ryu, T.Y. Kim, W.B. Kim, G.Y. Kwon, G. Gong, D.H. Moon, S.C. Kim, S.J. Hong, Y.K. Shong, 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J. Clin. Endocrinol. Metab. 92, 1630–1634 (2007)CrossRefPubMed
32.
go back to reference N.W. Hales, G.A. Krempl, J.E. Medina, Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? Am. J. Otolaryngol. 29, 113–118 (2008)CrossRefPubMed N.W. Hales, G.A. Krempl, J.E. Medina, Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? Am. J. Otolaryngol. 29, 113–118 (2008)CrossRefPubMed
33.
go back to reference N. Wang, H. Zhai, Y. Lu, Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J. Otolaryngol. Head Neck Surg. 42, 38 (2013). doi:10.1186/1916-0216-42-38 PubMedCentralCrossRefPubMed N. Wang, H. Zhai, Y. Lu, Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J. Otolaryngol. Head Neck Surg. 42, 38 (2013). doi:10.​1186/​1916-0216-42-38 PubMedCentralCrossRefPubMed
34.
go back to reference D. Vriens, J.H. de Wilt, G.J. van der Wilt, R.T. Netea-Maier, W.J. Oyen, L.F. de Geus-Oei, The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer 117, 4582–4594 (2011)CrossRefPubMed D. Vriens, J.H. de Wilt, G.J. van der Wilt, R.T. Netea-Maier, W.J. Oyen, L.F. de Geus-Oei, The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. Cancer 117, 4582–4594 (2011)CrossRefPubMed
35.
go back to reference S.H. Kwon, J.K. Yoon, Y.S. An, Y.S. Shin, C.H. Kim, D.H. Lee, K.S. Jo, S.J. Lee, Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer. J. Surg. Oncol. 110, 702–706 (2014)CrossRefPubMed S.H. Kwon, J.K. Yoon, Y.S. An, Y.S. Shin, C.H. Kim, D.H. Lee, K.S. Jo, S.J. Lee, Prognostic significance of the intratumoral heterogeneity of (18) F-FDG uptake in oral cavity cancer. J. Surg. Oncol. 110, 702–706 (2014)CrossRefPubMed
Metadata
Title
Predictive value of intratumoral heterogeneity of F-18 FDG uptake for characterization of thyroid nodules according to Bethesda categories of fine needle aspiration biopsy results
Authors
Seong-Jang Kim
Samuel Chang
Publication date
01-12-2015
Publisher
Springer US
Published in
Endocrine / Issue 3/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0620-z

Other articles of this Issue 3/2015

Endocrine 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.